Autobio Diagnostics Co., Ltd. (SHA: 603658)

Market Cap	23.08B
Revenue (ttm)	4.54B
Net Income (ttm)	1.29B
Shares Out	576.89M
EPS (ttm)	2.25
PE Ratio	17.77
Forward PE	16.39
Dividend	1.05 (2.63%)
Ex-Dividend Date	Jun 5, 2024

Volume	2,053,947
Open	40.74
Previous Close	40.70
Day's Range	39.81 - 40.81
52-Week Range	37.94 - 66.36
Beta	-0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Autobio Diagnostics

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products. It develops immunoassay, biochemistry, and microbiology products, as well as reagents; and instruments, as well as medical laboratory solutions. The company’s immunoassay products AutoLumo A1860 that provides user experience for small and medium size labs; an automated chemiluminescence immunoassay analyzer; AutoLumo A2000 Plus, an automatic chemiluminescence immunoassay analyzer; AutoLumo A1000, an au...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1998
• Employees: 5,539
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603658

Financial Performance

In 2023, 603658's revenue was 4.44 billion, an increase of 0.05% compared to the previous year's 4.44 billion. Earnings were 1.22 billion, an increase of 4.28%.